Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1726 to 1740 of 8901 results

  1. Pembrolizumab with chemotherapy for treating hormone receptor-positive HER2-negative locally recurrent inoperable or metastatic breast cancer [ID6285]

    In development Reference number: GID-TA11342 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Eneboparatide for treating chronic hypoparathyroidism [ID6532]

    In development Reference number: GID-TA11688 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Dupilumab for treating bullous pemphigoid [ID6479]

    In development Reference number: GID-TA11615 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]

    In development Reference number: GID-TA10623 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Technologies to improve detection of endometrial cancer

    Awaiting development Reference number: GID-HTE10083 Expected publication date: TBC

    Health technology evaluations
    Awaiting development

  6. Semaglutide for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6635]

    Awaiting development Reference number: GID-TA11847 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Veligrotug for treating thyroid eye disease [ID6636]

    Awaiting development Reference number: GID-TA11839 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease [ID6343]

    In development Reference number: GID-TA11379 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. UX111 for treating mucopolysaccharidosis type IIIA [ID6540]

    Awaiting development Reference number: GID-TA11701 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Bladder cancer: diagnosis and management (update)

    In development Reference number: GID-NG10452 Expected publication date: TBC

    NICE guideline
    In development

  11. Prostate cancer: diagnosis and management (update)

    In development Reference number: GID-NG10451 Expected publication date: TBC

    NICE guideline
    In development

  12. Fenebrutinib for treating relapsing multiple sclerosis [ID6577]

    Awaiting development Reference number: GID-TA11775 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Norucholic acid for treating primary sclerosing cholangitis [ID6583]

    Awaiting development Reference number: GID-TA11782 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Pegcetacoplan for treating primary complement 3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis in people 12 years and over [ID6489]

    In development Reference number: GID-TA11633 Expected publication date:  18 June 2026

    Technology appraisal guidance
    In development

  15. Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239]

    In development Reference number: GID-TA11116 Expected publication date:  29 July 2026

    Technology appraisal guidance
    In development